Navigation Links
WuXi PharmaTech (NYSE: WX) Ranked the 28th of Deloitte Technology Fast 50 China
Date:10/26/2007

SHANGHAI, China, Oct. 26 /Xinhua-PRNewswire/ -- WuXi PharmaTech (NYSE: WX), China's premier provider of pharmaceutical R&D outsourcing services announced today that it has been ranked the 28th in the Deloitte Technology Fast 50 China program, a ranking of the 50 fastest growing technology companies in China. The awards ceremony was held in the JW Marriott Hotel Shanghai at Tomorrow Square, Shanghai on October 25.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

The Deloitte Technology Fast 50 China program ranks leading companies in Technology, Media and Telecom (TMT) sectors based on their average revenue growth rates over the last three years. Given China's rapid economic growth, the strong development of the TMT industry, the government advocating technology innovation and the appetite of local and overseas venture capital for fast growing technology companies, this year's revenue growth requirement for winning has substantially increased. As a result, more than half of the winners are the first time winners and only one of the top 10 winners is a previous winner.

Ranked the 22nd, 27th and 28th in 2005, 2006 and 2007, respectively, WuXi PharmaTech is one of the nine companies to win the award for three consecutive years.

''We are pleased to be recognized by Deloitte for our accomplishments for the third time," commented Dr. Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech. "As the whole industry sector enjoys remarkable growth, WuXi PharmaTech has grown from a small start-up to a New York Stock Exchange listed company. I am very proud that we still can maintain our relative rank on the list, and I would like to take this opportunity to thank our customers for their strong support and employees for their dedication and hard work," continued Dr. Li.

About WuXi PharmaTech

Founded in 2000, Shanghai-based WuXi PharmaTech is the leading China-based pharmaceutical and biotechnology R&D outsourcing company. As a research- driven and customer-focused company, WuXi PharmaTech provides pharmaceutical and biotechnology companies a broad and integrated portfolio of laboratory and research manufacturing services throughout the drug discovery and development process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug discovery and development by providing cost-effective and efficient outsourcing solutions that save its customers both time and money. Its operations are grouped into two segments: laboratory services, consisting of discovery chemistry, service biology, analytical, toxicology, pharmaceutical development and process development services, and manufacturing, focusing on manufacturing of advanced intermediates and active pharmaceutical ingredients for R&D use. In 2006, WuXi PharmaTech provided services to 70 pharmaceutical and biotechnology customers, including nine of the top ten pharmaceutical companies in the world, as measured by 2006 total revenues. For more information, please visit: http://www.wuxipharmatech.com.

For more information, please contact:

Sherry Shao

Tel: +86 (21) 5046-4002

Email: pr@pharmatechs.com


'/>"/>
SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. UW-Madison MBA program ranked among best for investment return
2. Madison top-ranked In Digital Cities Survey
3. Oshkoshs Pierce Security Vehicle Ranked in top 100 Technological Innovations for 2003
4. Wisconsin Companies Ranked Top in Nation in IT
5. Innovative Tissue Array Technology for High-Throughput Screening of Gene Expression
6. HotMasterAn innovative Hot Start/Cold Stop technology for better PCR* results
7. Enhancing Ruggedness and Full-Scan MS Sensitivity Using Ion Sweep Technology
8. Novel MicroRNA Array Technology for Sensitive miRNA Profiling
9. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
10. Use of FlashPlate Technology for In Vitro Measurement of [35S]-GTPγS Binding in CHO Cells Expressing the Human 5-HT1B Receptor
11. Use of Novel FlashPlate Technology to Measure cAMP Accumulation in Chinese Hamster Ovary Cells Expressing Human -2 Adrenoreceptors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... , January 20, 2017 ... is one of leading causes of death worldwide. There ... the number of cancer related deaths increased gradually over ... in incidence rate of various cancers continues to drive ... research report by Global Market Insights, Inc. cancer biological ...
(Date:1/19/2017)... Jan. 19, 2017 /PRNewswire -- WuXi AppTec, a ... capability and technology platform, today announced that it ... focused preclinical drug discovery contract research organization (CRO). ... a wholly-owned subsidiary of WuXi, and will continue ... providing greater services. The acquisition will further strengthen ...
(Date:1/19/2017)... CALABASAS, Calif. , Jan. 19, 2017 /PRNewswire/ ... Mathias Schmidt , Ph.D., as chief executive ... board of directors. Dr. Schmidt brings to ArmaGen more ... on the research and development of biotherapeutics and ... biopharmaceutical executive with the diverse experience and skillset ...
(Date:1/19/2017)... (PRWEB) , ... January 19, 2017 , ... ... organization with services spanning the full spectrum of drug and device development, and ... services to pharma/device companies and clinicians, today announced Verified Clinical Trials ...
Breaking Biology Technology:
(Date:12/15/2016)... Dec. 15, 2016   WaferGen Bio-systems, Inc. ... technology company, announced today that on December 13, 2016, ... of The Nasdaq Stock Market LLC which acknowledged that, ... of WaferGen,s common stock had been at $1.00 or ... regained compliance with Listing Rule 5550(a)(2) of the Nasdaq ...
(Date:12/15/2016)... "Increase in mobile transactions is driving the growth of ... expected to grow from USD 4.03 billion in 2015 ... of 29.3% between 2016 and 2022. The market is ... smart devices, government initiatives, and increasing penetration of e-commerce ... to grow at a high rate during the forecast ...
(Date:12/7/2016)... -- According to a new market research report "Emotion Detection and ... Recognition), Service, Application Area, End User, And Region - Global Forecast to 2021", ... Billion in 2016 to USD 36.07 Billion by 2021, at a Compound Annual ... ... MarketsandMarkets Logo ...
Breaking Biology News(10 mins):